+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Measles - Pipeline Review, H1 2020

  • ID: 5024728
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 43 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Biological E Ltd
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • Enesi Pharma Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • MORE
Measles - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Measles - Pipeline Review, H1 2020, provides an overview of the Measles (Infectious Disease) pipeline landscape.

Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing and sneezing can spread the infection. Symptoms of measles are high temperature, sore eyes (conjunctivitis), and a runny nose usually occur first, small white spots usually develop inside the mouth a day or so later, diarrhea and vomiting.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Measles - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Measles (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Measles (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Measles and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 2 and 1 molecules, respectively.

Measles (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Measles (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Measles (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Measles (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Measles (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Measles (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Measles (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Measles (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biological E Ltd
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • Enesi Pharma Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Measles - Overview
  • Measles - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Measles - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Measles - Companies Involved in Therapeutics Development
  • Biological E Ltd
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • Enesi Pharma Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Micron Biomedical Inc
  • Panacea Biotec Ltd
  • Sinovac Biotech Ltd
  • Univercells SA
  • VBI Vaccines Inc
  • Measles - Drug Profiles
  • (measles + mumps + rubella + varicella) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles + mumps + rubella) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles + rubella) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles + rubella) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles + rubella) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles + rubella) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles + rubella) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles [strain Edmonston-Zagreb] + mumps [strain Hosino] + rubella [strain RA 27/3]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BK-1601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ERDRP-0519 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • measles vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • measles vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VN-0102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Measles - Dormant Projects
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Measles, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Measles - Pipeline by Biological E Ltd, H1 2020
  • Measles - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Measles - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Measles - Pipeline by Enesi Pharma Ltd, H1 2020
  • Measles - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Measles - Pipeline by Indian Immunologicals Ltd, H1 2020
  • Measles - Pipeline by Micron Biomedical Inc, H1 2020
  • Measles - Pipeline by Panacea Biotec Ltd, H1 2020
  • Measles - Pipeline by Sinovac Biotech Ltd, H1 2020
  • Measles - Pipeline by Univercells SA, H1 2020
  • Measles - Pipeline by VBI Vaccines Inc, H1 2020
  • Measles - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Measles, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Biological E Ltd
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • Enesi Pharma Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Micron Biomedical Inc
  • Panacea Biotec Ltd
  • Sinovac Biotech Ltd
  • Univercells SA
  • VBI Vaccines Inc
Note: Product cover images may vary from those shown
Adroll
adroll